B-cell acute lymphoblastic leukemia

This trial tests a personalized therapy where a patient's own T cells are collected, genetically modified to recognize and attack CD19-positive leukemia cells, and then infused back into the patient. It is designed for children and young adults with relapsed or refractory CD19+ a…

This study tests a new type of immune cell therapy for people with CD19-positive leukemia or lymphoma who have had a stem cell transplant. The cells are specially designed to both recognize and kill cancer cells (through a CD19-targeting antibody) and fight three common viruses (…

This phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatr…

This early study tests a new gene therapy called INT2104 in 10 adults with B-cell cancers that have come back or not responded to treatment. The therapy is given as a single IV infusion and works by instructing the body to create its own cancer-fighting T cells and natural killer…

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…

This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…

This early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This phase II trial tests a personalized cell therapy called tisagenlecleucel (Kymriah) in children and young adults with high-risk B-cell acute lymphoblastic leukemia who still have detectable cancer cells after initial chemotherapy. The treatment involves collecting the patient…

This study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This phase II trial tests inotuzumab ozogamicin, a drug that targets and kills leukemia cells carrying a specific marker (CD22). It enrolls 40 adults with B-cell acute lymphoblastic leukemia who are in remission but still have minimal residual disease (MRD) — tiny amounts of canc…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This early-stage study tests a new cell therapy for adults with a hard-to-treat type of leukemia (ALL). Doctors take a patient's own white blood cells, add a special gene to help them find and kill cancer cells, and give them back after chemotherapy. The main goals are to check s…

This Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…

This study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1 to 21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a guided missile, attaching to a marker (CD22) on cancer cel…

This study compares a targeted immune therapy called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1-30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away long…

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive…

This early-phase study tests a new biologic drug called PIT565 in 61 adults with B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The main goals are to check the drug's safety, find the best dose, and see ho…

This early-phase trial is testing a new treatment called MB-CART19.1 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better r…

This early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) along with a special stem cell transplant (Orca-T) is safe for adults with a high-risk type of leukemia called B-cell ALL. The approach is designed to help the donor cells attack the…

This study tests whether the targeted drug inotuzumab ozogamicin can eliminate minimal residual disease (MRD) in adults with B-cell acute lymphoblastic leukemia (ALL) before they receive a stem cell transplant. Participants have either Philadelphia chromosome-positive or -negativ…

This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…

This phase II trial is testing whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy can help older adults with B-cell acute lymphoblastic leukemia or lymphoma. The study compares the combination to standard chemo alone in 68 participants. The goal …

This study tests a one-time treatment using the patient's own immune cells, modified to target a protein called CD22 on leukemia cells. It is for children and young adults whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The main goa…

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is…

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells…

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatme…

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back af…

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…

This study tests a subcutaneous (under the skin) injection of blinatumomab for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or minimal residual disease. The goal is to see if this new method is safe and effective. About 181 adults and adolescents…

This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…

This study was designed to test a new treatment called BAFFR CAR-T for people with B-cell blood cancers that came back or didn't respond to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. However, the trial was withdrawn before en…

This study tests a subcutaneous (under the skin) injection of blinatumomab in children under 12 with relapsed/refractory or minimal residual disease positive B-cell acute lymphoblastic leukemia. The goal is to see if this easier-to-give form is safe and effective at achieving rem…

This phase 2 trial tests whether adding the targeted antibody tafasitamab to a standard chemotherapy regimen (DA-EPOCH, with or without rituximab) can improve outcomes for adults newly diagnosed with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). Th…

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to…

This study tests a treatment called AUTO1, a type of CAR T cell therapy, in 153 adults whose B cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, engineering them to recognize and attac…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This early-phase study tests a new type of immunotherapy called BAFFR-CAR T cells for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The therapy involves reprogramming a patient's own immune cells to recognize…

This study tests whether giving a second dose of the CAR T-cell therapy tisagenlecleucel early can keep the immune system's B cells low for at least 6 months in children and young adults with relapsed B-cell acute lymphoblastic leukemia. The goal is to reduce the chance of the ca…

This study tests a drug called blinatumomab in 18 children (ages 1 month to 18 years) in China whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatment. The goal is to see if the drug can bring about complete remission and to check for side ef…

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …

This study tests FDA-approved CAR-T cell therapy in 150 children and adults with certain blood cancers that have come back or not responded to treatment. Participants receive their own immune cells that have been reprogrammed to attack cancer cells. The goal is to see how many pa…

This study looks at how well a treatment called CNCT-19 works for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (ALL). Researchers will review medical records from 275 patients across multiple hospitals in China to see how many achieve remission an…

This study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatm…

This early-phase study tests a new treatment for people with certain blood cancers (lymphoma or leukemia) that have returned after a stem cell transplant. Researchers take immune cells called T cells from the original stem cell donor, modify them to recognize and attack cancer ce…

This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain B-cell blood cancers who are getting CAR-T treatment will receive anakinra. The goal i…

This early-stage trial tests a new approach for adults with acute lymphoblastic leukemia that has not responded to chemotherapy. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells with CD22 and CD19 proteins, and infuse them…

This phase 2 trial tests whether giving two drugs—blinatumomab and venetoclax—after a stem cell transplant can prevent relapse in adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study enrolls 24 people aged 14 to 65. The main goal is to see how many stay ca…

This early-stage trial is testing a new drug called GNC-035, a special antibody that targets four different signals on cancer cells. It is being given to 33 adults with blood cancers like lymphoma or leukemia that have come back or not responded to other treatments. The main goal…

This early-phase trial tests whether adding pulses of the cancer drug dasatinib to standard CAR T-cell therapy (brexucabtagene autoleucel) is feasible and safe for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Eight participants receive dasatinib on a we…

This early-stage trial tests a personalized therapy where a patient's own immune cells are genetically modified to recognize and attack cancer cells that carry a protein called CD19. It includes adults with certain types of leukemia, lymphoma, or chronic lymphocytic leukemia that…

This study looks back at the medical records of 102 adults with B-cell acute lymphoblastic leukemia who received the drug inotuzumab ozogamicin. The goal is to see how well the drug worked and how safe it was. No new treatments are given; researchers are just gathering existing d…